HIV Scientific Papers
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
2009
Antimicrob Agents Chemother.
Jacobson JM, Kuritzkes DR, Godofsky E, et al.
53(2):450-457.
Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations.
2009
Michaud S-E, Abolfathi Z, Potvin D, et al.
"Poster #P3-641 presented at: ENDO; June 10-13, 2009; Washington, DC, USA.
"
Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers.
2009
Vincent G, Teng S, Ducharme MP, et al.
Poster #P178. Presented at: the 18th Annual Canadian Conference on HIV/AIDS Research (CAHR); April 24-27, 2009; Vancouver, British Columbia, Canada.
Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in hiv-infected patients with excess abdominal fat. a pooled analysis of 2 multicenter, double-blind placebo-controlled phase 3 trials with 816 randomized patients [abs ...
2009
Falutz J, Mamputu J-C, Potvin D, et al.
The 18th Annual Canadian Conference on HIV/AIDS Research (CAHR); April 24-27, 2009; Vancouver, British Columbia, Canada.
Atherogenic lipid profile in treated HIV patients with increased visceral adiposity:association with more severe CVD risk parameters and response to tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue.
2009
Falutz J, Mamputu J-C, Marsolais C, et al.
Poster #713 presented at: Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montréal, Québec, Canada.